View in EDS

A new therapeutic strategy for infectious diseases against intracellular multidrug-resistant bacteria.

Saved in:
Bibliographic Details
Title: A new therapeutic strategy for infectious diseases against intracellular multidrug-resistant bacteria.
Authors: Wang, Zhao-Jie1 (AUTHOR), Zhu, Yan-Yan1 (AUTHOR), Bai, Li-Yu1 (AUTHOR), Tang, Dong-Mei1 (AUTHOR), Zhou, Zhong-Shun1 (AUTHOR), Wei, Mei-Zhen1 (AUTHOR), He, Jin-Biao1 (AUTHOR), Yu-Duan1 (AUTHOR), Luo, Xiao-Dong1,2 (AUTHOR) xdluo@ynu.edu.cn
Source: Journal of Controlled Release. Nov2024, Vol. 375, p467-477. 11p.
Subjects: Methicillin-resistant staphylococcus aureus, Protein synthesis, Bacterial diseases, Enterococcus, Communicable diseases
Abstract: Bacterial infections result in 7,700,000 deaths per year globally, with intracellular bacteria causing repeated and resistant infection. No drug is currently licenced for the treatment of intracellular bacteria. A new screening platform mimicking the host milieu has been established to explore phytochemical antibiotic adjuvants. Previously neglected isoprenylated flavonoids were found to be effective against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Specifically, the synergistic effect between glabrol and streptomycin against intracellular bacteria was observed for the first time. The glabrol-streptomycin combination targets bacterial inner membrane phospholipids, disrupts arginine biosynthesis, inhibits cell wall proteins and biofilm formation genes (agrA/B/C/D), and promotes ROS production, causing subsequent membrane and wall damage. To enhance the selective uptake of combination drug into infected cells, hyaluronic acid-streptomycin-lipoic acid-glabrol nanoparticles (HSLGS-S) were designed and synthesized to trigger the intracellular delivery of the glabrol-streptomycin combination. Thus, the treatment can be transported into the infected intracellular region and selectively release the glabrol-streptomycin combination to the bacterial at site. The bioactivity of HSLGS-S in clearing intracellular bacteria was 20-fold higher than that of the glabrol-streptomycin combination alone in vitro and 2- to 10-fold higher in vivo. [Display omitted] • A new screening platform to explore antibiotic adjuvants with the previously neglected phytochemicals. • Glabrol-streptomycin destroyed bacterial inner membrane, arginine biosynthesis, the cell wall proteins and biofilm formation. • HSLGS-S against intracellular MDR bacteria in vivo and in vitro. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Controlled Release is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
FullText Text:
  Availability: 0
Header DbId: egs
DbLabel: Engineering Source
An: 180295787
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A new therapeutic strategy for infectious diseases against intracellular multidrug-resistant bacteria.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Wang%2C+Zhao-Jie%22">Wang, Zhao-Jie</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zhu%2C+Yan-Yan%22">Zhu, Yan-Yan</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bai%2C+Li-Yu%22">Bai, Li-Yu</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tang%2C+Dong-Mei%22">Tang, Dong-Mei</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zhou%2C+Zhong-Shun%22">Zhou, Zhong-Shun</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wei%2C+Mei-Zhen%22">Wei, Mei-Zhen</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22He%2C+Jin-Biao%22">He, Jin-Biao</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Yu-Duan%22">Yu-Duan</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Luo%2C+Xiao-Dong%22">Luo, Xiao-Dong</searchLink><relatesTo>1,2</relatesTo> (AUTHOR)<i> xdluo@ynu.edu.cn</i>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Journal+of+Controlled+Release%22">Journal of Controlled Release</searchLink>. Nov2024, Vol. 375, p467-477. 11p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Methicillin-resistant+staphylococcus+aureus%22">Methicillin-resistant staphylococcus aureus</searchLink><br /><searchLink fieldCode="DE" term="%22Protein+synthesis%22">Protein synthesis</searchLink><br /><searchLink fieldCode="DE" term="%22Bacterial+diseases%22">Bacterial diseases</searchLink><br /><searchLink fieldCode="DE" term="%22Enterococcus%22">Enterococcus</searchLink><br /><searchLink fieldCode="DE" term="%22Communicable+diseases%22">Communicable diseases</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Bacterial infections result in 7,700,000 deaths per year globally, with intracellular bacteria causing repeated and resistant infection. No drug is currently licenced for the treatment of intracellular bacteria. A new screening platform mimicking the host milieu has been established to explore phytochemical antibiotic adjuvants. Previously neglected isoprenylated flavonoids were found to be effective against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Specifically, the synergistic effect between glabrol and streptomycin against intracellular bacteria was observed for the first time. The glabrol-streptomycin combination targets bacterial inner membrane phospholipids, disrupts arginine biosynthesis, inhibits cell wall proteins and biofilm formation genes (agrA/B/C/D), and promotes ROS production, causing subsequent membrane and wall damage. To enhance the selective uptake of combination drug into infected cells, hyaluronic acid-streptomycin-lipoic acid-glabrol nanoparticles (HSLGS-S) were designed and synthesized to trigger the intracellular delivery of the glabrol-streptomycin combination. Thus, the treatment can be transported into the infected intracellular region and selectively release the glabrol-streptomycin combination to the bacterial at site. The bioactivity of HSLGS-S in clearing intracellular bacteria was 20-fold higher than that of the glabrol-streptomycin combination alone in vitro and 2- to 10-fold higher in vivo. [Display omitted] • A new screening platform to explore antibiotic adjuvants with the previously neglected phytochemicals. • Glabrol-streptomycin destroyed bacterial inner membrane, arginine biosynthesis, the cell wall proteins and biofilm formation. • HSLGS-S against intracellular MDR bacteria in vivo and in vitro. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Journal of Controlled Release is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=egs&AN=180295787
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jconrel.2024.09.028
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 11
        StartPage: 467
    Subjects:
      – SubjectFull: Methicillin-resistant staphylococcus aureus
        Type: general
      – SubjectFull: Protein synthesis
        Type: general
      – SubjectFull: Bacterial diseases
        Type: general
      – SubjectFull: Enterococcus
        Type: general
      – SubjectFull: Communicable diseases
        Type: general
    Titles:
      – TitleFull: A new therapeutic strategy for infectious diseases against intracellular multidrug-resistant bacteria.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Wang, Zhao-Jie
      – PersonEntity:
          Name:
            NameFull: Zhu, Yan-Yan
      – PersonEntity:
          Name:
            NameFull: Bai, Li-Yu
      – PersonEntity:
          Name:
            NameFull: Tang, Dong-Mei
      – PersonEntity:
          Name:
            NameFull: Zhou, Zhong-Shun
      – PersonEntity:
          Name:
            NameFull: Wei, Mei-Zhen
      – PersonEntity:
          Name:
            NameFull: He, Jin-Biao
      – PersonEntity:
          Name:
            NameFull: Yu-Duan
      – PersonEntity:
          Name:
            NameFull: Luo, Xiao-Dong
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: Nov2024
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 01683659
          Numbering:
            – Type: volume
              Value: 375
          Titles:
            – TitleFull: Journal of Controlled Release
              Type: main
ResultId 1